... York, NY, October 30, 2008 Bayhill Therapeutics, Inc., ... the Juvenile Diabetes Research Foundation, the world,s leading charitable ... partnership to support Bayhill,s ongoing Phase I/II human clinical ... immune response that causes type 1 diabetes. , BHT-3021 ...
... for typically include a sense of power, great negotiating skills ... it is not just an outgoing personality and great communication ... group. Previous research has implicated that there is a gender ... leader may depend on the specific situation that a group ...
... D.C. Researchers at Georgetown University Medical Center ... cells become resistant to tamoxifen, the world,s largest-selling breast ... could provide a way to identify tamoxifen users who ... to try another therapy option sooner. , In the ...
Other Biology News:Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 2Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 3Gender biases in leadership selection during competitions within and between groups 2Gender biases in leadership selection during competitions within and between groups 3'New' estrogen receptor found to be key player in tamoxifen resistance 2'New' estrogen receptor found to be key player in tamoxifen resistance 3(Date:12/11/2009)... -- EntreMed, Inc. (Nasdaq: ENMD ), today ... revenue from sales of Thalomid® during the third ... million. In addition, the Company anticipates a ... fiscal 2009. The difference in estimated and ... reflected in the fourth quarter financial results. ,, ...
(Date:12/11/2009)... December 2009 -- Researchers have discovered a new explanation for ... more excess copies of a certain gene, the more serious ... and it is suspected that it is the amount of ... are being published in the American Journal of Human ... group of Guy Froyen connected to VIB, a life sciences ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
(Date:12/11/2009)... Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the ... Warrander to the role of Senior Vice President, ... will be responsible for the execution of the ... Thompson, President and CEO of Oncolytics. "Having reached ... 3 trial examining REOLYSIN in combination with paclitaxel ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2Amount of gene surplus determines severity of mental retardation in males 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3